Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EGFRvIII/DR5/NY-ESO-1/Mesothelin CAR-T/TCR-T Cells Immunotherapy for Solid Malignancies

NCT03941626 is registered in ClinicalTrials.gov with Shenzhen BinDeBio Ltd. as lead sponsor.

NCT NCT03941626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03941626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EGFRvIII/DR5/NY-ESO-1/Mesothelin CAR-T/TCR-T Cells Immunotherapy for Solid Malignancies
Lead sponsor
Shenzhen BinDeBio Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 1, 2019
Completion date
December 1, 2021
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophagus cancer, gastric cancer, glioma, hepatoma